The Library

A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya : comparison between Rotarix and RotaTeq vaccines

Tools

van Hoek, Albert Jan, Ngama, Mwanajuma, Ismail, Amina, Chuma, Jane, Cheburet, Samuel, Mutonga, David, Kamau, Tatu and Nokes, D. James. (2012) A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya : comparison between Rotarix and RotaTeq vaccines. PLoS One, Vol.7 (No.10). e47511. ISSN 1932-6203

[img]
Preview
 Text
WRAP_Nokes_Cost_effectiveness_capacity.pdf - Published Version
Available under License Creative Commons Attribution.
Download (433Kb) | Preview

Abstract

Background

Diarrhoea is an important cause of death in the developing world, and rotavirus is the single most important cause of diarrhoea associated mortality. Two vaccines (Rotarix and RotaTeq) are available to prevent rotavirus disease. This analysis was undertaken to aid the decision in Kenya as to which vaccine to choose when introducing rotavirus vaccination.

Methods

Cost-effectiveness modelling, using national and sentinel surveillance data, and an impact assessment on the cold chain.

Results

The median estimated incidence of rotavirus disease in Kenya was 3015 outpatient visits, 279 hospitalisations and 65 deaths per 100,000 children under five years of age per year. Cumulated over the first five years of life vaccination was predicted to prevent 34% of the outpatient visits, 31% of the hospitalizations and 42% of the deaths. The estimated prevented costs accumulated over five years totalled US$1,782,761 (direct and indirect costs) with an associated 48,585 DALYs. From a societal perspective Rotarix had a cost-effectiveness ratio of US$142 per DALY (US$5 for the full course of two doses) and RotaTeq US$288 per DALY ($10.5 for the full course of three doses). RotaTeq will have a bigger impact on the cold chain compared to Rotarix.

Conclusion

Vaccination against rotavirus disease is cost-effective for Kenya irrespective of the vaccine. Of the two vaccines Rotarix was the preferred choice due to a better cost-effectiveness ratio, the presence of a vaccine vial monitor, the requirement of fewer doses and less storage space, and proven thermo-stability.

Item Type: Journal Article
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Divisions: Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH): Rotavirus infections -- Vaccination -- Cost effectiveness
Journal or Publication Title: PLoS One
Publisher: Public Library of Science
ISSN: 1932-6203
Official Date: 24 October 2012
Dates:
DateEvent
24 October 2012Published
Volume: Vol.7
Number: No.10
Page Range: e47511
Identification Number: 10.1371/journal.pone.0047511
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
References:

1. World Health Organisation (2009) Rotavirus vaccines: an update. Weekly
epidemiological record: 533–540.
2. GAVI Alliance (2011) List of countries eligible for GAVI support. Available:
http://www.gavialliance.org/support/apply/countries-eligible-for-support/.
Accessed 2011 Aug 5.
3. Kenya National Bureau of Statistics (2010) Demographic and health survey
2008–2009.
4. Division for the Control of Diarrhoeal and Acute Respiratory Disease (1994)
Appendix R: converting 2-week diarrhoea prevalence to 2-week incidence.
Household Survey Manual: Diarrhoea and Acute Respiratory Infections.
Geneva: World Health Organization.
5. Kenya National Bureau of Statistics website. Census 2009. Available: http://
kenya.socrata.com/. Accessed 2011 Aug 5.
6. Nokes DJ, Abwao J, Pamba A, Peenze I, Dewar J, et al. (2008) Incidence and
clinical characteristics of group A rotavirus infections among children admitted to hospital in Kilifi, Kenya. PLoS medicine 5: e153. doi:10.1371/journal.
pmed.0050153.
7. Ruuska T, Vesikari T (1990) Rotavirus disease in Finnish children: use of
numerical scores for clinical severity of diarrhoeal episodes. Scandinavian
journal of infectious diseases 22: 259–267.
8. Madhi S, Cunliffe N, Steele D, Witte D (2010) Effect of human rotavirus vaccine
on severe diarrhea in African infants. New England Journal of Medicine 362:
289–298.
9. Armah G, Sow S, Breiman R, Dallas M (2010) Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in developing countries
in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. The
Lancet 376: 606–614. doi:10.1016/S0140–6736(10)60889–6.
10. Ombok M, Adazu K, Odhiambo F, Bayoh N, Kiriinya R, et al. (2010)
Geospatial distribution and determinants of child mortality in rural western
Kenya 2002–2005. Tropical medicine & international health: TM & IH 15:
423–433. doi:10.1111/j.1365–3156.2010.02467.x.
11. GlaxoSmithKline (2009) WHO Package insert Rotarix (liquid formulation).
12. Merck & Co Inc. (2008) Package insert RotaTeq: 11. doi:10.1086/653546.
13. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, et al. (2009) Oral
rotavirus vaccines: how well will they work where they are needed most? The
Journal of infectious diseases 200 Suppl: S39–48. doi:10.1086/605035.
14. Fischer Walker CL, Black RE (2011) Rotavirus vaccine and diarrhea mortality:
quantifying regional variation in effect size. BMC public health 11 Suppl 3: S16.
doi:10.1186/1471–2458–11-S3-S16.
15. Cortese MM, Parashar UD (2009) Prevention of Rotavirus Gastroenteritis
Among Infants and Children Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 58: 1–25.
16. Advisory Committee on Immunization Practices (1999) Withdrawal of Rotavirus
Vaccine Recommendation. MMWR 48: 1007.
17. Rothman KJ, Young-Xu Y, Arellano F (2006) Age dependence of the relation
between reassortant rotavirus vaccine (RotaShield) and intussusception. Journal
of Infectious Diseases 193: 898.
18. Flessa S, Moeller M, Ensor T, Hornetz K (2011) Basing care reforms on
evidence: The Kenya health sector costing model. BMC Health Services
Research 11: 128. doi:10.1186/1472–6963–11–128.
19. Kenya National Bureau of Statistics (2011) Consumer Price Index. Available:
http://www.knbs.or.ke/consumerpriceindex.php. Accessed 2011 Jul 29.
20. Ministry of Medical Services and Public Health (2009) Household Health
Expenditure Survey Report 2007. Nairobi, Kenya. p.
21. Tate JE, Rheingans RD, O’Reilly CE, Obonyo B, Burton DC, et al. (2009)
Rotavirus disease burden and impact and cost-effectiveness of a rotavirus
vaccination program in kenya. The Journal of infectious diseases 200 Suppl:
S76–84. doi:10.1086/605058.
22. World Health Organisation (2004) Global Burden of Disease 2004 update:
Disability weigths for diseases and conditions.
23. Murray C, Lopez A (1996) The global burden of disease: a comprehensive
assessment of mortality and disability from diseases, injuries and risk factors in
1990 and projected to 2020. Cambridge, MA (USA): Harvard University Press.
p.
24. PATH. Cold Chain Equipment Manager. Available: http://www.path.org/
projects/cold-chain-ccem.php. Accessed 2011 Aug 5.
25. GSK website. (2011) Millions of children in the world’s poorest countries could
receive vaccination against rotavirus diarrhoeal disease under new offer made by
GSK to the GAVI Alliance. Available: http://www.gsk.com/media/
pressreleases/2011/2011-pressrelease-462284.htm. Accessed 2011 Aug 5.
26. Merck & Co Inc (2011) Merck commends GAVI alliance on continued efforts to
improve access. Available: http://www.merck.com/newsroom/news-releasearchive/
corporate-responsibility/2011_0605.html. Accessed 2011 Aug 5.
27. Lopman BA, Curns AT, Yen C, Parashar UD (2011) Infant rotavirus
vaccination may provide indirect protection to older children and adults in
the United States. The Journal of infectious diseases 204: 980–986. doi:10.1093/
infdis/jir492.
28. Girma B, Berhane Y (2011) Children who were vaccinated, breast fed and from
low parity mothers live longer: a community based case-control study in Jimma,
Ethiopia. BMC public health 11: 197. doi:10.1186/1471–2458–11–197.
29. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global,
regional, and national causes of child mortality in 2008: a systematic analysis.
Lancet 375: 1969–1987. doi:10.1016/S0140–6736(10)60549–1.
30. Esposito DH, Tate JE, Kang G, Parashar UD (2011) Projected impact and costeffectiveness
of a rotavirus vaccination program in India, 2008. Clinical
Infectious Diseases 52: 171–177. doi:10.1093/cid/ciq094.
31. Zaman K, Anh DD, Victor JC, Shin S, Yunus M, et al. (2010) Efficacy of
pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in
developing countries in Asia: a randomised, double-blind, placebo-controlled
trial. The Lancet 376: 615–623. doi:10.1016/S0140–6736(10)60755–6.
32. Nokes DJ, Peenze I, Netshifhefhe L, Abwao J, De Beer MC, et al. (2010)
Rotavirus genetic diversity, disease association, and temporal change in
hospitalized rural Kenyan children. The Journal of infectious diseases 202
Suppl: S180–6. doi:10.1086/653566.
33. Kiulia NM, Kamenwa R, Irimu G, Nyangao JO, Gatheru Z, et al. (2008) The
epidemiology of human rotavirus associated with diarrhoea in Kenyan children:
a review. Journal of tropical pediatrics 54: 401–405. doi:10.1093/tropej/
fmn052.
34. Nyangao J, Page N, Esona M, Peenze I, Gatheru Z, et al. (2010)
Characterization of human rotavirus strains from children with diarrhea in
Nairobi and Kisumu, Kenya, between 2000 and 2002. The Journal of infectious
diseases 202 Suppl: S187–92. doi:10.1086/653564.
35. WHO. Cost effectiveness threshold CHOICE. Available: http://www.who.int/
choice/costs/CER_thresholds/en/index.html. Accessed 2011 Aug 5.
36. Atherly DE, Lewis KDC, Tate J, Parashar UD, Rheingans RD (2012) Projected
health and economic impact of rotavirus vaccination in GAVI-eligible countries:
2011–2030. Vaccine 30: A7–A14. doi:10.1016/j.vaccine.2011.12.096.
37. Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, Vanprapar N,
Simasathien S, et al. (2011) Immunogenicity of a human rotavirus vaccine
(RIX4414) after storage at 37uC for seven days. Human Vaccines 7: 74–80.
38. WHO. Vaccine characteristics. Available: http://www.who.int/immunization_
standards/vaccine_quality/PQ_vaccine_list_en/en/index.html. Accessed 2011
Aug 5.
URI: http://wrap.warwick.ac.uk/id/eprint/52019

Request changes or add full text files to a record

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics